Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals to treat cancer and other life-threatening disorders.

Cantex's pipeline features two products in phase II clinical development:

  • CX-02, a proprietary combination of disulfiram + copper, is in phase II trials for recurrent glioblastoma and metastatic castration-resistant prostate cancer. Cantex expects to initiate an additional phase II trial in metastatic triple-negative breast cancer in early 2018. Top-line results of these phase II trials are expected in 2018
  • CX-01, a polysaccharide, is a new chemical entity that is being developed for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. A randomized phase IIB trial of CX-01 in newly diagnosed AML is currently enrolling patients. Separately, Cantex is currently enrolling patients in a phase II trial in patients with myelodysplastic syndrome and expects to initiate a phase II trial in patients with severe traumatic brain injury in early 2018. Top-line results of these phase II trials are expected in 2018

 

Latest News

Spotlight

Cantex has two products in phase II clinical development:

CX-02:

  • Highly active against glioblastoma, prostate cancer, triple-negative breast cancer, and other cancers in pre-clinical studies
  • Unique proprietary formulation combining two compounds with well-established safety
  • Phase II trials in recurrent glioblastoma and metastatic castration-resistant prostate cancer underway; an additional phase II trial in metastatic triple-negative breast cancer is expected to begin in early 2018

CX-01:

  • Inhibits activity of HMGB1, a protein implicated in chemotherapy resistance and in the secondary injury following severe traumatic brain injury
  • 75-patient randomized phase IIB study in newly diagnosed AML now enrolling
  • Phase II trial in patients with myelodysplastic syndrome is also currently underway
  • An additional phase II trial in patients with severe traumatic brain injury seeking to control intracranial pressure is expected to begin in early 2018